anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Shaped structures such as fibres, flocks, fabrics, felts or foils, of linear aromatic polyesters are dyed or printed with a dyestuff of the formula:-  <FORM:0865308/IV(c)/1> in which X represents a halogen atom or an alkyl, alkoxy, aryl or cyano group and n one of the numbers 0, 1 or 2, at least one n being other than zero.  Dyeing or padding may be effected at 80 DEG -100 DEG C. in the presence of carriers such as benzoic acid, o-hydroxybenzoic acid or their methyl esters, or diphenyl or its 2- or 4-hydroxy derivatives.  Dyeing may also be effected at temperatures above 100 DEG C. under pressure. Prints are subsequently heated or steamed.  Numerous examples are given.  The dyestuffs are made by condensing phthalic acid or its anhydride, amide or imide with 2-methyl-3-hydroxy-quinoline and subsequently introducing the halogen atoms or the above specified groups into the condensate.  Alternatively, one or both constituents of the condensation product may contain the halogen atoms or the above specified groups prior to condensation.
A vaginal discharge collection (250) device is formed of an elastomeric rim (252) and a flexible film reservoir (254). The rim (252) may have a generally rectangular cross section and forms a collection space for collecting vaginal discharge. The reservoir (254) may be collapsible so as to be substantially enclosed within the rim (252) when the device is being used. Advantageously, the rim (252) and the reservoir (254) are arranged such that compressing diametrically opposed portions of the rim (252) toward each other causes a leading portion of the rim (252) to dip downwardly to facilitate insertion of the device. The device is ergonomically constructed so as to be convenient to use, comfortable to wear internally, and reliable. A system for reliably, comfortably and conveniently introducing agents, including drugs and other substances, into the vaginal canal is also disclosed.
The cGAS-STING signaling pathway plays a critical role in innate immunity and defense against viral infections by orchestrating intracellular and adaptive immune responses to DNA. In the context of head and neck squamous cell carcinoma (HNSCC), this pathway has garnered significant attention due to its potential relevance in disease development and progression. HNSCC is strongly associated with risk factors such as smoking, heavy alcohol consumption, and human papillomavirus (HPV) infection. The presence or absence of HPV in HNSCC patients has been shown to have a profound impact on patient survival and prognosis, possibly due to the distinct biological characteristics of HPV-associated tumors. This review aims to provide a comprehensive overview of the current therapeutic approaches and challenges in HNSCC management, as well as the involvement of cGAS-STING signaling and its potential in the therapy of HNSCC. In addition, by advancing the present understanding of the mechanisms underlying this pathway, Activation of cGAS-STING-dependent inflammatory signaling downstream of chromosomal instability can exert both anti-tumoral and pro-tumoral effects in a cell-intrinsic manner, suggesting individualized therapy is of great importance. However, further exploration of the cGAS-STING signaling pathway is imperative for the effective management of HNSCC.
In this study, we investigate the effect of neuregulin 4 (NRG4) on podocyte damage in a mouse model of diabetic nephropathy (DN) and we elucidate the underlying molecular mechanisms. In vivo experiments were conducted using a C57BL/6 mouse model of DN to determine the effect of NRG4 on proteinuria and podocyte injury, and in vitro experiments were performed with conditionally immortalized mouse podocytes treated with high glucose and NRG4 to assess the protective effects of NRG4 on podocyte injury. Autophagy-related protein levels and related signaling pathways were evaluated both in vivo and in vitro. The involvement of the adenosine monophosphate-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway was detected using chloroquine or AMPK inhibitors. The results showed that the AMPK/mTOR pathway was involved in the protective roles of NRG4 against high glucose-mediated podocyte injury. Also, NRG4 significantly decreased albuminuria in DN mice. PAS staining indicated that NRG4 mitigated glomerular volume and mesangium expansion in DN mice. Consistently, western blot and RT-PCR analyses confirmed that NRG4 decreased the expression of pro-fibrotic molecules in the glomeruli of DN mice. The immunofluorescence results showed that NRG4 retained expression of podocin and nephrin, whereas transmission electron microscopy revealed that NRG4 alleviated podocyte injury. In DN mice, NRG4 decreased podocyte apoptosis and increased expression of nephrin and podocin, while decreasing the expression of desmin and HIF1α. Overall, NRG4 improved albuminuria, glomerulosclerosis, glomerulomegaly, and hypoxia in DN mice. The in vitro experiments showed that NRG4 inhibited HG-induced podocyte injury and apoptosis. Furthermore, autophagy of the glomeruli decreased in DN mice, but reactivated following NRG4 intervention. NRG4 intervention was found to partially activate autophagy via the AMPK/mTOR signaling pathway. Consequently, when the AMPK/mTOR pathway was suppressed or autophagy was inhibited, the beneficial effects of NRG4 intervention on podocyte injury were diminished. These results indicate that NRG4 intervention attenuates podocyte injury and apoptosis by promoting autophagy in the kidneys of DN mice, in part, by activating the AMPK/mTOR signaling pathway.
The pain assessment in animals is challenging as they cannot verbally express the site and severity of pain. In this study, we tried a small implantable actimeter, "Nanotag", to monitor spontaneous locomotor activity and body temperature in animals suffering from a chemical-induced rat knee arthritis as compared to naïve and steroid-treated rats. Nanotag could detect the decrease in locomotor activity quickly after the arthritis induction and anti-inflammation analgesic treatment by intra-articular injection of steroid significantly improved locomotor activity. These changes were in the same line with those of a conventional knee pain evaluation method (incapacitance test). Nanotag can be utilized as the non-interventional, continuous, and completely objective monitoring the amount of pain in rat knee arthritis model. This traditional yet innovative method may be universally applicable to various pain models and species, making it a worthwhile device for research across diverse fields.
<P>PROBLEM TO BE SOLVED: To provide a thermoprotecting agent for the hair for preventing hair damages, particularly formation of lanthionine, caused by a heat treatment.  <P>SOLUTION: The thermoprotecting agent for the hair comprises as a thermoprotecting material at least one selected from the group consisting of a protein hydrolysate, a protein hydrolysate derivative and a polyamino acid, each exhibiting a film-forming property. The thermoprotecting material is preferably a keratin hydrolysate having an average amino acid polymerization degree of 100-500. The protein hydrolysate derivative is preferably a silylated derivative. The content of the protein hydrolysate and/or the protein hydrolysate derivative and/or the polyamino acid in the thermoprotecting agent for the hair is preferably 0.05-20 mass%.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The King Vision video laryngoscope used in this study has a 45° angulation, with a disposable No. 3 blade and no channel for the orotracheal tube.
All subjects receive HepQuant SHUNT Liver Diagnostic Test within 42 days of the scheduled EGD. Test includes 20mg of 13C Cholate mixed with Albumin via IV push, and 40mg of d4 Cholate mixed with juice orally, both doses given simultaneously one time.
A pyrogen-free aqueous solution of a sodium or potassium salt of a calcium chelate compound of an alkylene-polyamine polyacetic acid at pH 7.2-7.4 is used for medical injection.  Diamine tetra-acetic acids mentioned are ethylene diamine tetra-acetic acid, trimethylene diamine tetra-acetic acid, propylene diamine tetra-acetic acid, 1,2-cyclohexylene diamino N,N-tetra-acetic acid, diethyl ether b,b1-diamino N,N1-tetra-acetic acid, ethylene glycol 1,2-ethylene ether o ,o 1, diamino N,N1, tetra-acetic acid.  In the preparation of the sodium calcium complex of ethylene diamine tetraacetic acid, a solution in pyrogen-free water of the repeatedly crystallized acid is reacted with a pyrogen-free solution of 2 mols. sodium hydroxide with stirring and gentle heating, and 1 mol. calcium chloride, acetate, oxide, hydroxide carbonate &c. is then added with agitation and heating.  The pH of the solution is finally brought to 7.2 to 7.4 by addition of sodium or potassium hydroxide, or of hydrochloric, citric or acetic acid.ALSO:A preparation for reducing, by base exchange, the content of toxic metal ions which may be present in the system consists of a pyrogen-free aqueous solution of an alkali metal, particularly the disodium or dipotassium, salt of a calcium chelate compound of a diamine N, N1 tetra acetic acid of pH 7.2-7.4.  The solution may be injected, or taken into the body by ingestion or by skin absorption.  Thus, the solution may be evaporated to dryness, and the solid incorporated in a tablet with dextrose, or gelatin-coated.  Or the solution may be mixed with a water-miscible ointment to form an emulsion containing 5 per cent of the active ingredient.  Diamine tetra acetic acids mentioned are ethylene diamine tetra acetic acid, trimethylene diamine tetra acetic acid, proplyene diamine tetra acetic acid, 1, 2 cyclohexylene diamino N, N1 tetra acetic acid, diethyl ether b, b1 diamino N, N1 tetra acetic acid, ethylene glycol 1, 2 ethylene ether o 1 o 1 diamino N, N1 tetra acetic acid.  The preparation of the complex of ethylene diamine tetra acetic acid is described, (see Group IV(b)), the pH of the solution being finally brought to 7.2-7.4 by addition of sodium or potassium hydroxide, or of hydrochloric, citric or acetic acid.
The surgeon uses a laparoscopic technique to visualise the peritoneum from the inside of the abdomen and guides the hypodermic needle through the abdominal wall from the outside. When the needle point is visible through the peritoneum and almost enters the abdominal cavity, the surgeon retracts the needle around 5 mm. Then by deploying a test dose of the local anaesthetics a so called "Doyle's bulge" sign can confirm the right position in the nervous plane. A dose of 20 cc 3,75 mg/ml of Ropivacain is administered on each side of the abdominal wall in the midaxillary line, just in between the crista and costal margin.
The present invention relates to a method for preparing a gastrointestinal function improving composition using vegetable polysaccharide polymers. The method includes: a washing step, an extraction and filtering step, a concentration step, an ethanol processing step, an ethanol separation step, a drying step, a foreign substance removing step, and a mixing step. The wormwood (Artemisia capillaris) and green tea (Camellia sinensis) are washed in the washing step. A first extract and a second extract are extracted from the washed wormwood and green tea respectively in the extraction and filtering step. The first and second extracts are concentrated to prepare a first concentrate and a second concentrate in the concentration step. The first and second concentrates are stirred with ethanol in the ethanol processing step. The ethanol is separated from the first and second concentrate in the ethanol separation step to separate a first polysaccharide and a second polysaccharide. The first and second polysaccharides are dried in the drying step. The foreign substances in the dried first and second polysaccharides are removed in the foreign substance removing step. The first and second polysaccharides after the foreign substance removing step are mixed together in the mixing step. The present invention suppresses the Helicobacter pylori bacteria causing stomach disease from being attached to the inner gastrointestinal wall and prevents the inflammation thereof.
Subjects will be randomized to 1 of 3 lenses (Test/Control 1/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
The invention relates to a cefmenoxime hydrochloride drug composition for children, namely, a drug composition preparation of cefmenoxime hydrochloride and a low-sodium carrier infusion solution, in particular to a composition application package. The composition comprises the cefmenoxime hydrochloride and the low-sodium carrier infusion solution for injection. The low-sodium carrier infusion solution comprises a dextrose and sodium chloride injection (15-200:1), a glucose, sodium chloride and potassium chloride injection (15-200:1:0-1) and the like. Relative to the compatible and mixed use of the cefmenoxime hydrochloride and the low-sodium carrier infusion solution, clinical application steps are simplified. The clinical risks caused due to the fact that the kidneys of the children are not mature and are incapable of metabolizing too much sodium existing in blood are reduced. The clinical application quality and safety of child drugs are improved.
Skin and soft tissue reactions secondary to extravasation have been observed after administration of PADCEV. Of the 720 patients treated with PADCEV as a single agent in clinical trials, 1% of patients experienced skin and soft tissue reactions, including 0.3% who experienced Grade 3-4 reactions. Reactions may be delayed. Erythema, swelling, increased temperature, and pain worsened until 2-7 days after extravasation and resolved within 1-4 weeks of peak. Two patients (0.3%) developed extravasation reactions with secondary cellulitis, bullae, or exfoliation. Ensure adequate venous access prior to starting PADCEV and monitor for possible extravasation during administration. If extravasation occurs, stop the infusion and monitor for adverse reactions.
The efficacy of the NASA SPRINT exercise countermeasures program for quadriceps (vastus lateralis) and triceps surae (soleus) skeletal muscle health was investigated during 70 days of simulated microgravity. Individuals completed 6° head-down-tilt bedrest (BR, n = 9), bedrest with resistance and aerobic exercise (BRE, n = 9), or bedrest with resistance and aerobic exercise and low-dose testosterone (BRE + T, n = 8). All groups were periodically tested for muscle (n = 9 times) and aerobic (n = 4 times) power during bedrest. In BR, surprisingly, the typical bedrest-induced decrements in vastus lateralis myofiber size and power were either blunted (myosin heavy chain, MHC I) or eliminated (MHC IIa), along with no change (P > 0.05) in %MHC distribution and blunted quadriceps atrophy. In BRE, MHC I (vastus lateralis and soleus) and IIa (vastus lateralis) contractile performance was maintained (P > 0.05) or increased (P < 0.05). Vastus lateralis hybrid fiber percentage was reduced (P < 0.05) and energy metabolism enzymes and capillarization were generally maintained (P > 0.05), while not all of these positive responses were observed in the soleus. Exercise offsets 100% of quadriceps and approximately two-thirds of soleus whole muscle mass loss. Testosterone (BRE + T) did not provide any benefit over exercise alone for either muscle and for some myocellular parameters appeared detrimental. In summary, the periodic testing likely provided a partial exercise countermeasure for the quadriceps in the bedrest group, which is a novel finding given the extremely low exercise dose. The SPRINT exercise program appears to be viable for the quadriceps; however, refinement is needed to completely protect triceps surae myocellular and whole muscle health for astronauts on long-duration spaceflights.NEW & NOTEWORTHY This study provides unique exercise countermeasures development information for astronauts on long-duration spaceflights. The NASA SPRINT program was protective for quadriceps myocellular and whole muscle health, whereas the triceps surae (soleus) was only partially protected as has been shown with other programs. The bedrest control group data may provide beneficial information for overall exercise dose and targeting fast-twitch muscle fibers. Other unique approaches for the triceps surae are needed to supplement existing exercise programs.
PURPOSE: A dental composite composition containing crystallized glass-ceramic is provided to manufacture a dental block for direct and indirect repairing materials with improved physical property. CONSTITUTION: A dental composite composition contains crystallized glass-ceramic, monomers and/or oligomers containing unsaturated double bond, a polymerization initiator, and nano-sized filler. The crystallized glass-ceramic is lucite glass-ceramic or lithium dicilicate glass-ceramic. The average particle diameter of the crystallized glass-ceramic particles is 0.2-4 um. The monomer with unsaturated double bond is a methylmethacrylate(MMA)-based monomer. The MMA-based monomer is a mixture of 2,2-bis-(4-(2-hydroxy-3-methacyloyl oxypropoxy)phenyl)propane(Bis-GMA) and triethylene glycol dimethacrylate(TEGDMA). The filler is an inorganic filler or/and organic filler.
FIELD: medicine, stomatology, phytotherapy. SUBSTANCE: invention relates to parapharmaceutical industry producing preparations for curative and prophylactic designations. Invention proposes preparation for treatment of inflammatory diseases in mouth cavity that contains active and accessory substances. As active substances the preparation contains dried concentrate of peppermint tincture, mint essential oil, cardamom ground fruits, dried concentrate of Saint-John's-wort tincture, dried concentrate of sage herb infusion, cinnamon ground bark, citric acid and also starch, calcium state and sugar as accessory substances taken in the definite ratio of components per a tablet with mass 0.55 g. Invention can be used for breathing refreshing and as an accessory agent in complex treatment of acute and chronic inflammatory diseases of mouth cavity being alternative in cases of individual intolerance of some components. EFFECT: enhanced effectiveness and valuable medicinal properties of supplement. 1 tbl
An antimicrobial formulation contains a pyridine thiol and a quinone. Preferably the quinone is a benzoquinone, a hydroquinone or a mixture thereof; in particular an alkyl-substituted benzo / hydroquinone (e.g. TBHQ, TBBQ). The pyridine thiol may be a pyrithione (e.g. copper or zinc pyrithione). The formulations may be used to treat microbial infections, for example skin and skin structure conditions such as acne. The formulation may be especially useful against propionibacteria (e.g. propionibacterium acnes).
PCT No. PCT/GB93/00503 Sec. 371 Date Dec. 27, 1994 Sec. 102(e) Date Dec. 27, 1994 PCT Filed Mar. 10, 1993 PCT Pub. No. WO93/17663 PCT Pub. Date Sep. 16, 1993A non-pressurized pharmaceutical inhalation composition includes a therapeutically effective amount of a particulate inhalation medicament. The medicament has a mass median diameter in the range 0.01 to 15  mu m. A particulate polysaccharide entrapped flavoring agent is included in the composition and has a mass median diameter in the range of 10 to 200  mu m. The composition can be used to practice a method for treatment of reversible obstructive airway disease which includes administering the pharmaceutical composition to a patient.
PURPOSE: To assess 2-year cumulative and functional patency of endovascular arteriovenous fistulae (endoAVF) created with the WavelinQ device.
MATERIALS AND METHODS: Patients who had fistulae created at a single center from December 2019 to December 2020 were included in this retrospective study. Forty-three patients underwent endoAVF creation (22 females, 21 males). Data collected included patient demographics, location of fistula creation, interventions performed, and brachial artery flow before and after creation. Two-year cumulative and functional patency rates were assessed with Kaplan-Meier method, and variables that affected patency and maturation were examined using Cox proportional hazards model.
RESULTS: Technical success was 95% (41/43), and in 4 patients, the fistula did not mature for dialysis use (9.7%). For the remaining 37 patients with endoAVF maturation, 25 had ulnar-ulnar fistulae, 10 had radial-radial fistulae, and 2 had interosseous artery-vein fistulae. Mean maturity time was 73 days, and brachial artery flow of >886 mL/min was predictive of maturation. Mean tunneled dialysis catheter removal time was 133 days. Number of interventions per patient-year was 0.38, where 8 were maturation procedures (5 vein elevations/transpositions and 3 coil embolizations) and 21 were maintenance angioplasties. Two-year cumulative/secondary and functional patency rates were 89.4% and 92.1%, respectively, with a mean follow-up of 665.7 days. Examined variables did not impact cumulative or functional patency. One adverse event was migration of coil to the heart, which was successfully retrieved at time of procedure.
CONCLUSIONS: Two-year patency of 89.4% and functional patency of 92.1% were observed after endoAVF creation with WavelinQ device.
Tailored Human milk fortification procedure Tailored milk fortification will be done twice a day (8 am and 8 pm) for each following 12 hour nursing shift. Standard fortification will be added first. The remainder amount of protein, lipids and carbohydrates required to meet the recommended by ESPGHAN doses will be acheived by adding single ingrediant nutrients.
This invention provides an isolated nucleic acid which encodes bcl-8. This invention also provides an oligonucleotide of at least 15 nucleotides capable of specifically hybridizing with a sequence of nucleotides within a nucleic acid which encodes bcl-8. Further, this invention provides an agent capable of blocking the expression of BCL-8. This invention also provides various methods of determining whether a subject is afflicted with diffuse large cell lymphoma. This invention further provides a method of determining whether a subject has a predisposition for diffuse large cell lymphoma. This invention further provides various methods of treating a subject afflicted with diffuse large cell lymphoma. This invention also provides various methods of preventing diffuse large cell lymphoma in a subject. This invention also provides pharmaceutical compositions for treating and/or preventing diffuse large cell lymphoma.